Informações de Regeneron Pharmaceuticals Inc | Histórico, dados financeiros e desempenho de mercado

Mais detalhes de Regeneron Pharmaceuticals Inc Empresa

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Informações da empresa

Código da empresaREGN

Nome da EmpresaRegeneron Pharmaceuticals Inc

Data de listagemApr 02, 1991

Fundado em1988

CEODr. Leonard S. Schleifer, M.D., Ph.D

Número de funcionários15106

Tipo de títulosOrdinary Share

Fim do ano fiscalApr 02

Endereço777 Old Saw Mill River Road

CidadeTARRYTOWN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal10591

Telefone17813705000

Sitehttps://www.regeneron.com/

Código da empresaREGN

Data de listagemApr 02, 1991

Fundado em1988

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

19.75K

+20.78%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Detalhamento da receita

Moeda: USDAtualizado em: dom, 6 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

EYLEA

4.77B

33.57%

Sanofi

4.53B

31.91%

Bayer

1.50B

10.55%

EYLEA HD

1.20B

8.46%

Libtayo

787.30M

5.54%

Other

1.42B

9.97%

Sem dados

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

EYLEA

4.77B

33.57%

Sanofi

4.53B

31.91%

Bayer

1.50B

10.55%

EYLEA HD

1.20B

8.46%

Libtayo

787.30M

5.54%

Other

1.42B

9.97%

Distribuição de ações

Atualizado em: sáb, 17 de mai

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

8.81%

Fidelity Management & Research Company LLC

6.97%

BlackRock Institutional Trust Company, N.A.

5.41%

State Street Global Advisors (US)

4.51%

JP Morgan Asset Management

3.84%

Other

70.45%

Investidores

Proporção

The Vanguard Group, Inc.

8.81%

Fidelity Management & Research Company LLC

6.97%

BlackRock Institutional Trust Company, N.A.

5.41%

State Street Global Advisors (US)

4.51%

JP Morgan Asset Management

3.84%

Other

70.45%

Tipos de investidores

Investidores

Proporção

Investment Advisor

45.92%

Investment Advisor/Hedge Fund

34.13%

Hedge Fund

3.49%

Pension Fund

2.63%

Research Firm

2.62%

Bank and Trust

2.00%

Individual Investor

1.97%

Sovereign Wealth Fund

1.18%

Insurance Company

0.08%

Other

5.98%

Participação acionária institucional

Atualizado em: dom, 19 de jan

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q1

2568

101.21M

95.28%

+386.44K

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

2023Q1

2366

99.66M

92.70%

-1.10M

2022Q4

2333

99.78M

93.16%

-1.62M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

9.24M

8.59%

-32.55K

-0.35%

Dec 31, 2024

Fidelity Management & Research Company LLC

7.97M

7.41%

-2.08M

-20.68%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

5.70M

5.3%

+193.71K

+3.52%

Dec 31, 2024

State Street Global Advisors (US)

4.83M

4.49%

-70.17K

-1.43%

Dec 31, 2024

JP Morgan Asset Management

5.24M

4.88%

-524.97K

-9.10%

Dec 31, 2024

Capital International Investors

4.74M

4.41%

+1.39M

+41.55%

Dec 31, 2024

Geode Capital Management, L.L.C.

2.43M

2.26%

+155.37K

+6.84%

Dec 31, 2024

Dodge & Cox

2.32M

2.16%

+9.38K

+0.41%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

2.24M

2.08%

+29.93K

+1.36%

Feb 28, 2025

T. Rowe Price Associates, Inc.

1.93M

1.8%

+810.47K

+72.07%

Dec 31, 2024

Ver Mais

ETFs Relacionados

Atualizado em: sex, 6 de jun

Nome

Proporção

Tema Neuroscience and Mental Health ETF

7.58%

Invesco Nasdaq Biotechnology ETF

5.48%

ProShares Ultra Nasdaq Biotechnology

5.22%

iShares Biotechnology ETF

4.94%

VanEck Biotech ETF

4.13%

Invesco Biotechnology & Genome ETF

3.6%

First Trust NASDAQ Pharmaceuticals ETF

3.39%

iShares Genomics Immunology and Healthcare ETF

3.01%

Simplify Health Care ETF

2.83%

Franklin Genomic Advancements ETF

2.78%

Ver Mais

Tema Neuroscience and Mental Health ETF

Proporção7.58%

Invesco Nasdaq Biotechnology ETF

Proporção5.48%

ProShares Ultra Nasdaq Biotechnology

Proporção5.22%

iShares Biotechnology ETF

Proporção4.94%

VanEck Biotech ETF

Proporção4.13%

Invesco Biotechnology & Genome ETF

Proporção3.6%

First Trust NASDAQ Pharmaceuticals ETF

Proporção3.39%

iShares Genomics Immunology and Healthcare ETF

Proporção3.01%

Simplify Health Care ETF

Proporção2.83%

Franklin Genomic Advancements ETF

Proporção2.78%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

Desdobramento de ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

Regeneron Pharmaceuticals Inc

529.240USD

Regeneron Pharmaceuticals Inc

529.240

Visão Geral

Empresa